Skip to content

Study · Not a test of the peptide alone · 1987

5 results

Selective photolabeling of high and low affinity binding sites for vasoactive intestinal peptide (VIP): evidence for two classes of covalent VIP-receptor complexes in intestinal cell membranes.

Robichon A, Marie JC

Endocrinology1 Mar 1987Cited by 11 (Europe PMC)

PMID3026793 (opens in a new tab)DOI10.1210/endo-120-3-978 (opens in a new tab)PepBankPUB-03026793
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    In HT 29 cells, the VIP derivative modified at arginyl residues 12 and 14 produced less cAMP than VIP at equimolar concentration.

    In plain wordsIn lab tests on HT 29 cells, a modified VIP derivative made much less cAMP than VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasecAMP production by [Az Bz Arg12-14]VIP
    Study

    n: not reported in source

    HT 29 cells and cell membranes
    Comparator
    VIP
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    cAMP production relative to VIP
    15%
    [Az Bz Arg12-14]VIP at 10(-10) M

    Source sentences

    Summary
    The level of cAMP produced in HT 29 cells by this derivative represented 15% of that obtained by VIP at equimolar concentration (10(-10) M).

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    The VIP derivative modified only at position 14 bound the receptor with a Kd of 0.5 nM, against 0.1 nM for labelled VIP (lower affinity than VIP, but still high).

    In plain wordsIn lab tests, a modified VIP derivative bound the VIP receptor less tightly than VIP did (0.5 nM versus 0.1 nM), but still strongly.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseReceptor binding affinity of [Az Bz Arg14]VIP
    Study

    n: not reported in source

    HT 29 cells and cell membranes
    Comparator
    VIP
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    Kd
    0.5 nM
    [125I-Tyr,Az Bz Arg14]VIP
    Kd
    0.1 nM
    [125I] VIP

    Source sentences

    Summary
    This analog retained a high binding affinity for receptor (Kd, 0.5 nM for [125I-Tyr,Az Bz Arg14]VIP vs. 0.1 nM for [125I] VIP)

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    The VIP derivative modified only at position 14 was biologically active, with cAMP production close to that of VIP.

    In plain wordsIn lab tests, a modified VIP derivative stimulated cAMP production almost as much as VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeAdenylate cyclase stimulation by [Az Bz Arg14]VIP
    Study

    n: not reported in source

    HT 29 cells and cell membranes
    Comparator
    VIP
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    cAMP production
    120 pmol/10(6) cells
    [Az Bz Arg14]VIP
    cAMP production
    140 pmol
    VIP

    Source sentences

    Summary
    was found to be biologically active, as judged by stimulation of adenylate cyclase activity (production of cAMP was 120 pmol/10(6) cells vs. 140 pmol for VIP at 10(-10) M)

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    Photolysis of the VIP derivative with HT 29 cell membranes stimulated adenylate cyclase, and the stimulation persisted despite repeated washings.

    In plain wordsIn lab tests, after light exposure a VIP derivative stuck to cell membranes and kept the cell enzyme active after washing.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePersistent adenylate cyclase stimulation after photolysis
    Study

    n: not reported in source

    HT 29 cells and cell membranes
    Comparator
    Washed membranes
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Photolysis of this analog in the presence of HT 29 cell membranes resulted in a stimulation of adenylate cyclase which persisted in spite of repeated washings.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement

    When low affinity binding sites were selectively photolabelled, the VIP derivative did not stimulate adenylate cyclase activity.

    In plain wordsIn lab tests, when only the weaker binding sites were labelled, the VIP derivative did not switch on the cell enzyme.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeAdenylate cyclase after photolabelling of low affinity sites
    Study

    n: not reported in source

    HT 29 cells and cell membranes
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    When low affinity binding sites were specifically photolabeled using a selective protection of high affinity sites by incubating membranes with 10(-10) M VIP for 5 min, the derivative did not stimulate adenylate cyclase activity.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.